Chime Biologics

What Chime Biologics does

Chime Biologics is a privately held biologics contract development and manufacturing organization (CDMO) founded in 2013 and headquartered in Wuhan, China, with additional operations in Shanghai (China Innovation Hub), Basel (European Innovation Hub opened June 2025), and sales offices in San Diego, Boston, and Paris. The company operates the world's first KUBio modular biopharmaceutical factory built with GE/Cytiva technology, using single-use bioreactors at 50L, 200L, 500L, and 2000L cGMP scales to manufacture monoclonal antibodies, bispecific antibodies, fusion proteins, conjugated proteins, enzymes, and vaccines. Its facilities are designed to meet NMPA, EMA, US FDA, and EU PIC/S GMP standards, and the company reports more than 70 successful 2000L GMP production batches and clinical material supply to clients across 30+ countries.

The company's service portfolio spans the full biologics development lifecycle: cell line development, process development, protein science, technology transfer, drug substance manufacturing, drug product manufacturing (including liquid fill, lyophilized fill and pre-filled syringe fill in isolators), quality systems, regulatory support, project management, and data integrity. In November 2025 it launched the Chime AI Platform in partnership with Opq Therapeutics, adding AI-enabled target screening, antibody design and optimization, AI-enhanced cell line development, and AI-integrated rapid CMC as adjacent offerings. The business operates on professional-services contracts with biotech and biopharmaceutical clients, priced project-by-project, and pursues co-development and strategic partnerships (e.g., Polpharma Biologics, SunRock Biopharma, Domain Therapeutics, Daewoong Pharmaceutical, Libang Pharmaceuticals, TNAX Biopharma) as a parallel go-to-market channel.

Chime generates revenue through negotiated CDMO contracts and strategic collaborations with global biotech and biopharmaceutical clients. Pricing is quote-based and varies with scope, scale and development stage, typical of the contract manufacturing industry. The company is scaling aggressively: a US$190 million Series A+ in May 2024 (led by VMS Group with Fidelity International and Panacea Venture) and a December 2025 Optics Valley Financial Holdings round are funding capacity expansion toward 140,000+ liters over five years, while the Chime Innovation Alliance and Basel hub extend its commercial reach across China, Europe, and APAC.

Name

Chime Biologics

Legal name

Chime Biologics (Wuhan) Co., Ltd.

Website

https://chimebiologics.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Chime Biologics is a privately held Chinese CDMO providing end-to-end biologics development and manufacturing — from cell line development through commercial drug substance and drug product supply — serving global biotech and pharmaceutical clients across 30+ countries via its Wuhan KUBio modular facility and Basel European Innovation Hub.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Contract Manufacturing (CDMO)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

Biologic API/Drug Substance Manufacturing Services (HLAAAKAA), Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)

Keywords

• Biologics contract manufacturing
• CDMO services
• Drug substance manufacturing
• Cell line development
• Biopharmaceutical development

Headquarters

HQ city

Wuhan

HQ country

China

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

1. CDMO Contract Manufacturing Services: Full-suite contract development and manufacturing organization (CDMO) services including cell line development, process development, protein science, technology transfer, drug substance manufacturing, drug product manufacturing, quality control/assurance, regulatory support, and project management. Revenue generated through service contracts and manufacturing agreements with biotech and pharmaceutical clients across the development lifecycle from preclinical through commercial stages.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Chime Biologics is a global Contract Development and Manufacturing Organization (CDMO) that provides end-to-end biologics manufacturing services for biotech and pharmaceutical companies. The company offers services spanning cell line development, process development, drug substance manufacturing (50L–2000L), drug product manufacturing, technology transfer, quality control, and regulatory support from pre-clinical through commercial stages. Its operations leverage the world's first GE KuBio modular biopharmaceutical manufacturing facility using single-use bioprocessing technology, complemented by the newly launched Chime AI Platform for AI-driven biologics discovery and development.

Product overview

Chime Biologics is a leading global CDMO (Contract Development and Manufacturing Organization) providing end-to-end biologics manufacturing services from pre-clinical support through clinical and commercial manufacturing. The portfolio consists of core service modules including Cell Line Development, Process Development, Protein Science Group, Technology Transfer, Drug Substance Manufacturing (M-DS), Drug Product Manufacturing (M-DP), Quality System, Regulatory Support, Project Management, and Data Integrity. These services are powered by key technology platforms: the KUBio modular biopharmaceutical factory (world's first modular facility using single-use bioreactors from GE/Cytiva), and the Chime AI Platform for AI-driven biologics development. Manufacturing capabilities span scales from 50L to 2000L bioreactors for diverse molecule types including monoclonal antibodies, bispecific antibodies, fusion proteins, conjugated proteins, enzymes, and vaccines.

Differentiator

Problem solved

Functional benefit

Products and services

• End-to-End CDMO Services

Quantifiable outcome

• Successfully completed over 70 batches of 2000L GMP production
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

Partnerships

Ten partnerships are on record, tiered major, regional, strategic, core and supporting.

• Beijing Libang Pharmaceutical (Libang Pharmaceuticals)majorStrategic or Co-development Partner · 10 December 2025Strategic collaboration to develop a biosimilar to Amgen's Blincyto (blinatumomab) for global markets. Chime Biologics will leverage its GMP manufacturing platform and regulatory expertise to support the biosimilar development program.
• TNAX BiopharmaregionalStrategic or Co-development Partner · 9 December 2025Strategic collaboration marking Chime Biologics' first partnership in Japan. TNAX Biopharma is a Japanese biotech company.
• Opq Therapeutics (奥泊生科)strategicTechnology or Integration · 2 November 2025Strategic collaboration on AI-driven biologics discovery. Opq provides advanced AI technology for target screening, antibody design, and optimization while Chime provides CMC capabilities. Co-founders include Nobel Laureate Michael Levitt.
• SunRock BiopharmamajorStrategic or Co-development Partner · 21 October 2025Strategic collaboration to develop SRB5, a novel anti-CCR9 monoclonal antibody targeting inflammatory bowel disease (IBD) with potential expansion into other immune-mediated inflammatory indications. SunRock Biopharma is a Spanish biotech company focused on next-generation therapeutic antibodies.
• Superlab SuissecoreTechnology or Integration · 6 June 2025Host facility for Chime Biologics' European Innovation Hub in Basel. Superlab Suisse provides laboratory space and infrastructure enabling Chime's operations in the heart of Europe's biotech ecosystem.
• Basel Area Business and InnovationsupportingStrategic or Co-development Partner · 6 June 2025Basel Area Business and Innovation is the official economic development agency for the Basel area. They support and promote the biotech ecosystem and welcomed Chime Biologics' establishment of European Innovation Hub in Basel.
• Chime Innovation Alliance PartnerscoreStrategic or Co-development Partner · 6 June 2025Alliance of leading Chinese biotech service providers providing one-stop solutions for customers from drug discovery through preclinical, clinical, and commercial stages. Partner companies include Sepax Bioscience, AnLing, Alioth Biotech, NanoMicro, Duoning Biotech, Lisure, and others.
• Japan-China Bio-Innovation Ecosystem Forum PartnerssupportingStrategic or Co-development Partner · 22 May 2025Co-organized with Duoning Biotech and Lisure to promote innovation, collaboration, and investment between Japan and China in the biopharmaceutical industry.
• Polpharma BiologicsmajorStrategic or Co-development Partner · 16 April 2025Strategic partnership with Poland-based Polpharma Biologics to support end-to-end development and manufacture of a biosimilar product for the global market. Chime provides integrated support from IND stage through commercial supply. Polpharma has two biosimilars approved by FDA and EMA.
• Domain TherapeuticsmajorStrategic or Co-development Partner · 12 March 2024Manufacturing agreement for DT-7012, a novel anti-CCR8 antibody for cancer immunotherapy. Chime provides cell line development, process development, scale-up, and Phase I GMP clinical manufacturing. DT-7012 is a potential best-in-class Treg-depleting antibody.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Lonza: Swiss-based global CDMO with extensive biologics manufacturing capabilities across mammalian and microbial platforms. Serves as the dominant Western incumbent in biologics CDMO, competing with Chime for large-pharma and biotech contracts across multiple regulatory jurisdictions.
• Catalent: Large US-headquartered CDMO with biologics fill-finish, cell line, and biomanufacturing capabilities as part of a broader services portfolio. Overlaps with Chime on biologics drug substance and drug product manufacturing while also serving injectables, oral, and inhalation delivery.

Direct peers

• Samsung Biologics: Korean-based global biologics CDMO with large-scale cGMP manufacturing capacity (expanding toward ~1M liters) and full lifecycle services from clinical to commercial supply. Direct competitor for global biotech CDMO contracts with overlapping mAb and bispecific capabilities.
• WuXi Biologics: China-headquartered, Hong Kong-listed global biologics CDMO offering end-to-end services from cell line development through commercial manufacturing. The most direct competitor to Chime Biologics in terms of geographic origin, service portfolio, and target customer base, with materially larger scale (~600,000L capacity).
• AGC Biologics: Global biologics CDMO with manufacturing sites in the US, Europe, and Japan, offering mammalian and microbial-based biologics development and manufacturing services. Comparable mid-large tier peer competing for similar global biotech CDMO engagements.
• Bora Pharmaceuticals: Taiwan-headquartered CDMO with rapidly expanding biologics manufacturing capabilities alongside its established small-molecule franchise. Emerging direct competitor in Asia-Pacific biologics CDMO space with similar growth-oriented capacity expansion trajectory.
• KBI Biopharma: US-headquartered biologics CDMO (acquired by JSR Life Sciences) offering process development, analytical services, and cGMP manufacturing. Comparable mid-tier peer with similar focus on mammalian cell-based biologics and competitive pressure in the same customer segment.
• Boehringer Ingelheim BioXcellence: German-headquartered biologics CDMO division of Boehringer Ingelheim offering contract manufacturing from cell line through commercial supply. Direct peer with comparable service portfolio and similar positioning in mammalian-cell biologics manufacturing for global biotech clients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/chime-biologics

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chime Biologics